Peak plasma PZA concentrations achieved at MTD as reported in Phase I clinical trials
| Dose (mg/m2) | Schedule | Peak plasma level (μm) | AUC (μm·h) | Ref. no. |
|---|---|---|---|---|
| 600 | 1-h i.v. every 3 wks | 2.17 ± 1.05 | 30 ± 25 | 10 |
| 750 | 3-h i.v. every 3 wks | 2.3 (range, 1.4–4.5) | 12 | |
| 150 | 1-h i.v. × 5 days every 3 wks | Day 1 2.5 (range, 0.7–11.3) | 12 | |
| Days 2–5 5.6 (range, 2.6–9.5) | ||||
| 281 | 24-h i.v. every 3 or 4 wks | 1.6 | 56 | 11 |